Search - tctmd.com

Displaying 141 - 160 of 643

Sort: Relevancy | Date

Presentation TCT 2023

Where Do We Go From Here? Evolving the Hypertension Program

Presenter: Michael Bloch

October 24, 2023

Presentation TCT 2023

Who Is the Perfect Candidate for RDN? A Case-Based Discussion

Presenter: Michel Azizi

October 24, 2023

Presentation TCT 2023

Controlling the Uncontrolled: How Big Is the RDN Population?

Presenter: Naomi Fisher

October 24, 2023

News Conference News TCT 2022

Pascal TEER Device Performs Well in Patients With Complex Anatomy

Yael L. Maxwell

September 26, 2022

News Conference News TCT 2022

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

Yael L. Maxwell

September 21, 2022

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Caitlin E. Cox

September 19, 2022

News Conference News TCT 2022

Surgical TAVI Explants Are Risky and Rising: STS Data Carry a Warning

Shelley Wood

September 19, 2022

Presentation TCT 2022

Discussion - What does this Field Need Next?

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

Who Should be Treated with uRDN?

Presenter: Naomi Fisher

September 19, 2022

Presentation TCT 2022

Discussion - Key Takeaways from the RADIANCE Clinical Program

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

Late-Breaking Evidence from RADIANCE II

Presenter: Michel Azizi

September 19, 2022

Presentation TCT 2022

Introduction and Objectives

Presenter: Felix Mahfoud

September 19, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Presenter: Naomi Fisher

September 18, 2022

Presentation TCT 2022

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

Presenter: Patrick O'Gara

September 18, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

Presentation TCT 2022

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Ajay Kirtane

September 18, 2022

Presentation TCT 2022

TCT 736: Saline Optical Coherence Tomography (OCT) to guide revascularizationin in a patient with severe renal impairment and multivessel coronary artery disease.

Presenter: George Besis

September 18, 2022

News Conference News TCT 2022

TRILUMINATE Pivotal Trial: First Data Support Safety, Efficacy of TriClip

Caitlin E. Cox

September 17, 2022

Advertisement

Where Do We Go From Here? Evolving the Hypertension Program

Who Is the Perfect Candidate for RDN? A Case-Based Discussion

Controlling the Uncontrolled: How Big Is the RDN Population?

Pascal TEER Device Performs Well in Patients With Complex Anatomy

CCTA in Patients With Prior CABG Cuts Complications of Invasive Angio: BYPASS-CTCA

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Surgical TAVI Explants Are Risky and Rising: STS Data Carry a Warning

Discussion - What does this Field Need Next?

Who Should be Treated with uRDN?

Discussion - Key Takeaways from the RADIANCE Clinical Program

Late-Breaking Evidence from RADIANCE II

Introduction and Objectives

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

TCT 736: Saline Optical Coherence Tomography (OCT) to guide revascularizationin in a patient with severe renal impairment and multivessel coronary artery disease.

TRILUMINATE Pivotal Trial: First Data Support Safety, Efficacy of TriClip

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content